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andMarrowTransplant Research (CIBMTR)database to assess
outcomes of 1248 patients 40 years of age or older who
received reduced-intensity conditioningornonmyeloablative
allogeneic hematopoietic transplantation (alloHCT) for non-
Hodgkin lymphoma between 2001 and 2007. Their analysis
focuses on age and whether this treatment option is
underutilized in older patients. This large data set is impor-
tant, as it contains much information on "real world" out-
comes that will assist physicians and patients balance the
risks and beneﬁts as they confront the difﬁcult decision about
whether to proceed with alloHCT.
Football coach Woody Hayes (or perhaps it was Darrell
Royal, but that is another discussion) said years ago that 3
things can happen when you pass a football, 2 of them bad.
Nevertheless, the forward pass has still become an increas-
ingly important part of football, though we should not forget
about the running game. Similarly, 3 things can also occur
after alloHCT, 2 of them bad, ie, death (with or without
relapse) or signiﬁcant graft-versus-host disease. The “carrot”
balancing those risks is the possibility of prolonged unmain-
tained remission. This report by McClune et al. [1] supplies
data based on common clinical characteristics, including age,
to help inform the discussion. The discussion is, of course,
affected by the expected outcomes for non-HCT options,
which vary signiﬁcantly by lymphoma subtype and disease
status, andare also rapidlychangingwithnew targeted agents
available and in development; our “running game” is
improving as well.
As noted byMcClune et al. [1], we need bettermeasures of
whowill beneﬁt as well as whowill be harmed with alloHCT.
In considering beneﬁt, it is somewhat surprising that histo-
logic subtype did not affect outcomes, somewhat at oddswith
another CIBMTR report [2]. One concern interpreting the dataFinancial disclosure: See Acknowledgments on page 906.
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aggressive subtypes, inparticular asmantle cell accounted for
42% of this group, as this type of lymphoma has different
biology and clinical behavior. As we further subdivide lym-
phomas on the basis of mutational landscape and biologic
drivers [3], eg, diffuse large B cell lymphoma of germinal
center or nonegerminal center origin, or having MYC  BCL2
translocations, it will be important to determine whether
graft-versus-leukemia effects and alloHCT outcomes over-
come different biologic underpinnings of lymphoma; that is,
does alloHCT overcome “bad biology?”
Relative beneﬁts of alloHCT are affected by advances in
nontransplantation therapies. Signiﬁcant advances with
B cell signaling inhibitors, proapoptotic agents, and new
antibody therapeutics provide new non-HCT options. The
Bruton’s tyrosine kinase inhibitor ibrutinib is now FDA
approved for previously treated chronic lymphocytic leuke-
mia [4] andmantle cell lymphoma [5], and it is active in other
indolent and some aggressive lymphomas. The PI3-kinase
delta inhibitor idelalisib and the proapoptotic BCL2 inhibitor
ABT-199 are likely to be approved soon. Novel antibodies and
antibody-drug conjugates are active [6]. We also must be
careful when comparing outcomes for the selected patients
who undergo alloHCT with the larger population of relapsed
patients included in studies of these new agents.
Pretransplantation evaluation is, in part, an attempt to
identify pre-existing functional status to limit the percentage
of patients for whom the procedure will be excessively toxic.
Systematic assessment and quantiﬁcation of comorbidities
areuseful, andwe look forward tomoreextensive reportingof
the HCT-comorbidity index (HCT-CI) incorporated into the
CIBMTR database [7], as well as further reﬁnements in the
ability to predict nonrelapse mortality [8]. Comparison of
populations undergoing HCT or not, adjusted by HCT-CI or
other comorbidity assessment, would be informative and
help address the recurring issue of selection bias inherent in
the transplantation population.
Balancing potential beneﬁt and risks,what canwenowtell
the patientwho is over age 55with relapsed lymphomawhen
we discuss these issues? Once we decide that the patient is a
suitable candidate for alloHCT, althoughwe canquibble about
the precise numbers, there are roughlyequal chances for cure,
disease relapse, or nonrelapsemortality (27% at 1 year for age
55 to 64 and 34% age65, more than one half of these by day
100 [1]). For the patient with relapsed aggressive lymphoma
after autologous stem cell transplantation (autoSCT), for
whom non-HCT options are limited and not curative, the
potential for cure is indeed encouraging and should not be
limited merely by age, at least up to age 75, based on these
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likely explains why older patients in this cohort predomi-
nantly had aggressive disease. Not having clear answers of
who will beneﬁt, we generally adopt a shared decision-
making process, involving physicians, patients, and patient
families. An interesting attempt to gain expert physician
guidance on the role of alloHCT in follicular lymphoma [9]
identiﬁed some areas of consensus, others of disagreement.
Relatively unexplored is decision-making from the patient
perspective, although there are some studies in the pediatric
population [10]. My anecdotal observations are that oncolo-
gists often focus on potential beneﬁts, whereas patients often
focus on risks of toxicity and especially mortality, particularly
if they have had prior autoSCT. It would be worth learning
more about decision-making from the patient standpoint to
better assist in the process.
This report byMcClune et al. [1] continues the long history
of CIBMTR contributions to the literature that help guide the
wide range of the decisions involved in stem cell trans-
plantation. Utility of these data in daily practice would be
strengthened by streamlining the analytic process so that
patients undergoing alloHCT more recently than 2007 are
included, as well as comparing outcomes with those in the
non-HCT populations adjusted for comorbidities, perhaps
adapting the HCT-CI to the nonestem cell transplantation
group or using comprehensive geriatric assessments. Mean-
while, recent advances in targeted therapies approved for
indolent and mantle cell lymphoma are already altering the
equation, and we anticipate similar advances for aggressive
lymphomas. Although reasonable people may have different
deﬁnitions of “encouraging,” these data do support the idea
that age alone should not be a deciding factor in alloSCT.Financial disclosure: See Acknowledgments on page 907.
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Milano et al. report a lack of evidence for cord colitis syn-
drome (CCS) after umbilical cord blood transplantation
(UCBT), instead positing acute graft-versus-host disease
(GVHD) as the source [1]. CCS was initially described as a
syndrome of noninfectious, antibiotic-responsive diarrhea
after UCBT [2]. The case deﬁnition of CCS required histo-
pathologic examination of endoscopic tissue that excluded
GVHD and other etiologies of diarrhea. Biopsies alsodemonstrated presence of chronic inﬂammation, deﬁned as
basal plasmacytosis, paneth cell metaplasia, architectural
distortion, and granulomas.
In the initial publication by Herrera et al. [2], patients
treated at the DanaeFarber Cancer Institute/Brigham and
Women’s Hospital Hematopoietic Stem Cell Transplantation
Service presented with severe diarrheal illness, fever, and
weight loss, and many required hospitalization. The cases
occurred late (median, 131 days) and rarely had antecedent
GVHD of the gut. Perhaps the most striking ﬁnding was that
all patients responded to metronidazole  ﬂoroquinalone.
One-half developed recurrent diarrhea upon cessation of an-
tibiotics, but all recaptured their response following reinsti-
tution. The histological features differed from classic acute
GVHD with a paucity of crypt apoptosis and evidence of
chronic inﬂammation, namely paneth cell metaplasia and
granulomas.
Several explanations for CCS have been proposed and
include delayed GVHD, Tropheryma whipplei infection,
transfusion-related acute gut injury (TRAGI), and a chronic
interferon-g response against the nondominant cord unit [3-
6]. More recently, shotgun DNA sequencing performed on
archived tissues from 2 patients with cord colitis revealed a
